A new antidepressant isn’t any more effective than current drugs on the market, despite the claims of the manufacturer, drug regulators have announced.
Vortioxetine, marketed as Brintellix, is a SSRI (serotonin reuptake inhibitor) drug that won approval several years ago in Europe as a treatment for depression and anxiety attacks-but German drug regulators have now discovered the manufacturer, Lundbeck, carried out only limited trials.
Lundbeck looked only at acute cases of panic and anxiety attacks, and failed to carry out a proper comparison with the existing drug of choice, Celexa (citalopram), say regulators at the German Institute for Quality and Efficiency in Health Care.
As a result, there is no evidence to suggest that vortioxetine offers any benefits over Celexa or psychotherapy.
(Source: German Institute for Quality and Efficiency in Health Care, August 11, 2015)